Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Mitacs brings innovation to more people in more places across Canada and around the world.
Learn MoreWe work closely with businesses, researchers, and governments to create new pathways to innovation.
Learn MoreNo matter the size of your budget or scope of your research, Mitacs can help you turn ideas into impact.
Learn MoreThe Mitacs Entrepreneur Awards and the Mitacs Awards celebrate inspiring entrepreneurs and innovators who are galvanizing cutting-edge research across Canada.
Learn MoreDiscover the people, the ideas, the projects, and the partnerships that are making news, and creating meaningful impact across the Canadian innovation ecosystem.
Learn MoreMajor depressive disorder (MDD) is a serious mental condition that often completely debilitates a client. MDD is typically treated with one of several currently available antidepressant medications. However, the response rate to any of these medications is only about 30%. Unfortunately, there are currently no means for a priori assessment of whether a specific person will respond to a particular medication. Thus, in prescribing a treatment for MDD, the psychiatrist must by necessity resort to a trial-and-error procedure. This can result in long delays before remission and significant stress on the health care system. In conjunction with collaborating psychiatrists, the applicant has developed a preliminary EEG-based machine learning (ML) methodology that can predict the response of a person to an SSRI medication (which is one of the classes of anti-depressant treatment) before the therapy beings. It is clear that such a capability, when fully developed, will vastly improve the treatment of MDD. However, before this system can be exploited in clinical applications, significant further development of the ML methodology is required. The objective of proposed research is therefore to develop new ML methods that can reliably predict response, not just to the SSRI class as is currently the case, but to a wider variety of pharmacological therapies. This requires development of new high-performance ML methods that are specific to this application.
Dr. James Reilly
Multiple
St. Joseph’s Hospital
Engineering - computer / electrical
Life sciences
McMaster University
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.